Menu
Home
Forums
Forums
Quick Links
Search Forums
Recent Posts
job listings
catering
whistleblower info
legal help
advertise on CP
submit press release
Menu
Log in
Sign up
Search titles only
Posted by Member:
Separate names with a comma.
Newer Than:
Search this thread only
Search this forum only
Display results as threads
More...
Useful Searches
Recent Posts
Cafepharma Message Boards | Pharma Sales, Device Sales, Lab Sales
Home
Forums
>
Pharma/Biotech Companies
>
Pfizer
>
Heard about Vascepa launch?
>
Reply to Thread
Name:
Verification:
Answer the above question:
(
CustomImgCaptcha
By
Surrey Forum
)
Message:
<p>[QUOTE="Anonymous, post: 4540214"]New AstraZeneca boss 'planning to launch cash bid' for US biopharmaceutical group Amarin</p><p><br /></p><p>Read more: <a href="http://www.dailymail.co.uk/money/mar...#ixzz2ADZVDs2h" target="_blank" class="externalLink ProxyLink" data-proxy-href="http://www.dailymail.co.uk/money/mar...#ixzz2ADZVDs2h" rel="nofollow">http://www.dailymail.co.uk/money/mar...#ixzz2ADZVDs2h</a> </p><p><br /></p><p>"AstraZeneca's new boss Pascal Soriot didn’t mess about when on his first day in the job he announced the suspension of the drugs group’s £2.8bn share buy-back programme.</p><p>Shareholders were obviously miffed, but analysts took it as a definite sign that he wanted to save the cash for earnings enhancing acquisitions. </p><p>Soriot recently spent up to £169m on the rights to an experimental kidney drug, but rumours now suggest he has something much bigger up his sleeve.</p><p><br /></p><p>AZ’s shares shed 38p to 2900p ahead of tomorrow’s third-quarter trading statement. </p><p>The fall was accompanied by speculation Soriot is planning to launch a cash bid for US biopharmaceutical group Amarin, whose shares moved against the trend on Wall Street yesterday with an early gain to $11.61.</p><p>AstraZeneca, along with other larger pharmaceutical companies such as Merck, Pfizer, Abbott and Eli Lilly, would apparently love to get their hands on Amarin for Vascepa, a prescription medicine which helps with the treatment for cardiovascular disease. It is the group’s first FDA approval product.</p><p><br /></p><p>US analysts are of the opinion that Amarin’s days of independence are numbered. </p><p>They reckon that Amarin now stands at the crossroads and appears to be waiting for a large pharmaceutical company, with a substantial cardiovascular or diabetes sales force, to come and swallow it whole.</p><p>William Tanner, analyst at Lazard Capital Markets, currently has a target price of $26 on Amarin as has Canaccord Genuity’s Ritu Baral. What does that tell you?"[/QUOTE]</p><p><br /></p>
[QUOTE="Anonymous, post: 4540214"]New AstraZeneca boss 'planning to launch cash bid' for US biopharmaceutical group Amarin Read more: [url]http://www.dailymail.co.uk/money/mar...#ixzz2ADZVDs2h[/url] "AstraZeneca's new boss Pascal Soriot didn’t mess about when on his first day in the job he announced the suspension of the drugs group’s £2.8bn share buy-back programme. Shareholders were obviously miffed, but analysts took it as a definite sign that he wanted to save the cash for earnings enhancing acquisitions. Soriot recently spent up to £169m on the rights to an experimental kidney drug, but rumours now suggest he has something much bigger up his sleeve. AZ’s shares shed 38p to 2900p ahead of tomorrow’s third-quarter trading statement. The fall was accompanied by speculation Soriot is planning to launch a cash bid for US biopharmaceutical group Amarin, whose shares moved against the trend on Wall Street yesterday with an early gain to $11.61. AstraZeneca, along with other larger pharmaceutical companies such as Merck, Pfizer, Abbott and Eli Lilly, would apparently love to get their hands on Amarin for Vascepa, a prescription medicine which helps with the treatment for cardiovascular disease. It is the group’s first FDA approval product. US analysts are of the opinion that Amarin’s days of independence are numbered. They reckon that Amarin now stands at the crossroads and appears to be waiting for a large pharmaceutical company, with a substantial cardiovascular or diabetes sales force, to come and swallow it whole. William Tanner, analyst at Lazard Capital Markets, currently has a target price of $26 on Amarin as has Canaccord Genuity’s Ritu Baral. What does that tell you?"[/QUOTE]
Your name or email address:
Do you already have an account?
No, create an account now.
Yes, my password is:
Forgot your password?
Stay logged in
Cafepharma Message Boards | Pharma Sales, Device Sales, Lab Sales
Home
Forums
>
Pharma/Biotech Companies
>
Pfizer
>
Heard about Vascepa launch?
>
Cafepharma Message Boards | Pharma Sales, Device Sales, Lab Sales
Home
Forums
>
Pharma/Biotech Companies
>
Pfizer
>
Heard about Vascepa launch?
>